Bilastine: a lifetime companion for the treatment of allergies. (3rd March 2020)

• Record Type: Journal Article
• Authors: Church, Martin K.; Tiongco-Recto, Marysia; Ridolo, Erminia; Novák, Zoltán
• Is Part Of: Current medical research and opinion. Volume 36:Number 3(2020)
• Page Start: 445
• Page End: 454
• Publication Date: 2020-03-03
• Subjects: Allergic rhinitis -- antihistamines -- bilastine -- urticaria; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2019.1681134
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: Bilastine is a potent and highly selective H1 -antihistamine approved for the treatment of allergic rhinoconjunctivitis and urticaria. This article summarizes available data on the use of bilastine in the treatment of allergic disorders in different age groups, including younger and older adults, and school-age children and adolescents. Methods: A PubMed literature search ("bilastine") was conducted on 25 February 2019. Additional literature known to the authors and identified from the reference lists of cited publications was included. Results: Bilastine is administered orally at a dose of 20 mg once daily in adults and adolescents aged ≥12 years and 10 mg once daily in children aged 6 to <12 years. Clinical trials have demonstrated its efficacy at improving nasal and ocular symptoms in patients with allergic rhinitis, and wheals and itching in patients with urticaria. It has a rapid onset of action and long duration of action. Bilastine does not undergo significant metabolism and does not interact with the CYP450 system, which limits its potential for drug-drug interactions. No dosage adjustments are required in patients with renal or hepatic impairment, or in the elderly. Bilastine is generally well tolerated, even when administered at above-standard doses. It does not exhibit anticholinergic effects or cardiotoxic effects, shows no central nervous system penetration and has minimal sedative properties. It has been shown to improve health-related quality of life. Conclusions: Bilastine is a suitable option for the treatment of patients with allergic rhinoconjunctivitis or urticaria across age groups from school-age children to elderly patients.